mRCC: promising new combinations lead to disruption in L1 and L2

Targeted therapies, particularly tyrosine kinase inhibitors (TKI) dominate the treatment of advanced/metastatic renal cell carcinoma (mRCC) in the first line. While new drugs have expanded the treatment options, significant opportunities remain in this highly competitive market.

Une image contenant personne, homme, intérieur, habits

Description générée automatiquement

Our new results clearly demonstrate this: the recent launches of promising new combinations in 1L lead to disruption within the traditionally very stable mRCC treatment. New combinations of TKI+IO (Keytruda+InlytaBavencio+Inlyta) and IO+IO (Opdivo+Yervoy) show in some European markets significant increases in 1L, on the cost of TKI monotherapy. This uptake of modern combinations comes mainly from a very specific subset of patients, e.g. patients with high risk factors and poor prognosis. 

Different dynamics are seen in 2L treatment of mRCC: a decline of IO mono is seen across all 5EU markets, being caused by an uptake in TKI mono and – still on a small basis – by combination therapy of IO+IO.

This is one of the many learnings from the syndicated research we have designed to monitor the evolution of mRCC management, capitalizing on our unique expertise in the mRCC market and in anonymized real-world data from patient chart-based research. This was designed with input from clients we have been working with for over 12 years on this topic. 

The survey offers 2 components:  

  • A Total Market review is run twice a year with over 350 oncologists treating mRCC patients in the EU 5 countries (plus urologists in DE). Over 2,000 patient record forms are collected every 6 months (6 PRFs per HCPs, last seen in 1L, last 3 in 2L+).  
  • A close monitoring of the Dynamic Market: the total market overview is complemented with monthly data collection for the dynamic part of the market, i.e. recent newly initiated or switched patients, in order to closely monitor all changes.  

Results for total market are available for Q4.2019 (W1), Q2.2020 (W2) and you can already subscribe to Q4.2020 data collection (W3) that just started.

Results for monthly dynamic market data are available since end of 2019 - starting with patients who have been initiated or switched in November 2019 and you can still subscribe to the forthcoming data collection. 

Interested in knowing more how to access results or subscribe to our syndicated survey?

Learn more now

Definitions - TKI: tyrosine kinase inhibitor, IO: immunotherapy